UroStream

The 2025 Pujiang Prostate Cancer Academic Congress, held in conjunction with the CSCO Prostate Cancer Committee (CSCO-PC) Annual Meeting, the CACA Genitourinary Oncology Committee (CACA-GO) Prostate Cancer Meeting, and the Chinese Prostate Cancer Consortium (CPCC) Annual Conference, took place in Shanghai from June 27–28. With the theme “Global Insight · Chinese Practice · Precision Breakthrough,” the event brought together leading domestic and international experts to share cutting-edge progress and clinical experience in prostate cancer. During the conference, Professor Xiaojie Bian of Fudan University Shanghai Cancer Center spoke with Oncology Frontier – Urology Frontier to discuss the current landscape and future prospects of innovative drug development for prostate cancer.

The “2025 Pujiang Prostate Cancer Academic Conference,” held from June 27 to 28 in Shanghai, was jointly organized with the Annual Meeting of the Chinese Society of Clinical Oncology Prostate Cancer Committee (CSCO-PC), the Chinese Anti-Cancer Association Genitourinary Oncology (CACA-GO) Prostate Cancer Conference, and the Chinese Prostate Cancer Consortium (CPCC) Annual Meeting. Themed “Global Wisdom · Chinese Practice · Precise Breakthroughs,” the event brought together domestic and international experts to exchange the latest advances and practical experience in prostate cancer.

The 2025 Pujiang Prostate Cancer Academic Conference—held from June 27 to 28 in Shanghai—was jointly hosted by the Chinese Society of Clinical Oncology Prostate Cancer Committee (CSCO-PC), the Chinese Anti-Cancer Association Genitourinary Oncology Committee (CACA-GO), and the China Prostate Cancer Consortium (CPCC). With the theme "Global Wisdom, Chinese Practice, and Precision Breakthroughs," the conference brought together leading experts from China and abroad to discuss the latest advances and best practices in prostate cancer care. At the meeting, Professor Qiang Wei from West China Hospital, Sichuan University, delivered an insightful presentation on treatment escalation and de-escalation in metastatic hormone-sensitive prostate cancer (mHSPC) and shared key clinical perspectives in an interview with Oncology Frontier – UroStream.

The “2025 Pujiang Prostate Cancer Academic Conference,” held in Shanghai from June 27 to 28, was jointly hosted alongside the Annual Meeting of the Chinese Society of Clinical Oncology Prostate Cancer Committee (CSCO-PC), the Prostate Cancer Subcommittee of the Chinese Anti-Cancer Association (CACA-GO), and the Chinese Prostate Cancer Consortium (CPCC). With the theme “Global Wisdom, Chinese Practice, and Precision Breakthroughs,” the event gathered leading domestic and international experts to share the latest advances and clinical insights in prostate cancer care. At the conference, Professor Xudong Yao, Director of the Department of Urology at Shanghai Tenth People’s Hospital (Tongji University Affiliated Tenth People’s Hospital), delivered a keynote presentation titled “Exploration and Outlook on the Comprehensive Management of Prostate Cancer.” In an interview with Oncology Frontier – UroStream, he discussed his team’s experience and scientific work in prostate cancer management.

In the field of minimally invasive urologic surgery, Chinese physicians have long stood at the forefront of global innovationfrom pioneering retroperitoneoscopic approaches tailored to Chinese anatomical features to developing dual-console and remote robotic surgical systems that lead international standards. At the 2025 Annual Meeting of the Chinese Urological Doctor Association (CUDA), Professor Liqun Zhou, former Director of the Peking University Institute of Urology and current President of The First Affiliated Hospital of Henan University, delivered a compelling presentation titled “Application of Domestic Robotic Systems in Urologic Surgery – The IUPU Experience.” In an exclusive interview with UroStream, he shared the journey of IUPU’s development and clinical application of domestically produced surgical robots and offered insights into their transformative potential across urology.

The 2025 Pujiang Prostate Cancer Academic Conference—jointly held with the Annual Meeting of the Chinese Society of Clinical Oncology Prostate Cancer Committee (CSCO-PC), the Chinese Anti-Cancer Association Genitourinary Oncology Committee (CACA-GO), and the Chinese Prostate Cancer Consortium (CPCC)—took place in Shanghai on June 27–28. At the conference, Professor Jianming Guo from Zhongshan Hospital, Fudan University, delivered a keynote presentation on “Managing Postoperative Complications After Prostate Cancer Surgery” and later shared additional insights in an interview with Oncology Frontier – UroStream, highlighting Zhongshan’s experience in perioperative enhanced recovery after surgery (ERAS) for prostate cancer patients.